Toremifene: Difference between revisions

Toremifene
	Black Box Warning
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

← Older edit Newer edit →

VisualWikitext

Revision as of 20:46, 9 February 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

WARNING: QT PROLONGATION :

See full prescribing information for complete Boxed Warning.

WARNING: QT PROLONGATION :

FARESTON has been shown to prolong the QTc interval in a dose- and concentration-related manner. Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided

Overview

Toremifene is a antineoplasic agent that is FDA approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. There is a Black Box Warning for this drug as shown here. Common adverse reactions include hot flashes, sweating, nausea and vaginal discharge.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.

Dosage

The dosage of FARESTON is 60 mg, once daily, orally. Treatment is generally continued until disease progression is observed.

DOSAGE FORMS AND STRENGTHS

Tablet is 60 mg, round, convex, unscored, uncoated, and white, or almost white, identified with TO 60 embossed on one side.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Toremifene in adult patients.

Non–Guideline-Supported Use

Fracture of vertebral column; Prophylaxis - Prostate cancer, Receiving androgen deprivation therapy^[1]

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Toremifene in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Toremifene in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Toremifene in pediatric patients.

Contraindications

Condition1

Warnings

WARNING: QT PROLONGATION :

See full prescribing information for complete Boxed Warning.

WARNING: QT PROLONGATION :

FARESTON has been shown to prolong the QTc interval in a dose- and concentration-related manner. Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided

Description

Precautions

Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Toremifene in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Toremifene in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

Drug

Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Toremifene in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Toremifene during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Toremifene with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Toremifene with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Toremifene with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Toremifene with respect to specific gender populations.

Race

There is no FDA guidance on the use of Toremifene with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Toremifene in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Toremifene in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Toremifene in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Toremifene in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Intravenous

Monitoring

There is limited information regarding Monitoring of Toremifene in the drug label.

Description

IV Compatibility

There is limited information regarding IV Compatibility of Toremifene in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

Description

Management

Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Toremifene in the drug label.

Pharmacology

There is limited information regarding Toremifene Pharmacology in the drug label.

Mechanism of Action

Structure

File:Toremifene01.png

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Toremifene in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Toremifene in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Toremifene in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Toremifene in the drug label.

How Supplied

Storage

There is limited information regarding Toremifene Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Toremifene |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Toremifene |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Toremifene in the drug label.

Precautions with Alcohol

Alcohol-Toremifene interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

®^[2]

Look-Alike Drug Names

A® — B®^[3]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D; et al. (2010). "Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer". J Urol. 184 (4): 1316–21. doi:10.1016/j.juro.2010.06.022. PMC 3047407. PMID 20723926.
↑ Empty citation (help)
↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Toremifene
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Toremifene
 |Label Name=Toremifene11.png

}}

{{#subobject:

 |Label Page=Toremifene
 |Label Name=Toremifene11.png

}}

[pmid20723926-1] Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D; et al. (2010). "Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer". J Urol. 184 (4): 1316–21. doi:10.1016/j.juro.2010.06.022. PMC 3047407. PMID 20723926.

[2] Empty citation (help)

[www.ismp.org-3] "http://www.ismp.org". External link in |title= (help)

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
-|authorTag=<!--Overview-->
+|authorTag=<!--Overview-->{{RB}}
+|genericName=Toremifene Citrate
 |aOrAn=a
+|drugClass=antineoplasic agent
+|indicationType=treatment
+|indication=metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors
 |hasBlackBoxWarning=Yes
-|adverseReactions=<!--Black Box Warning-->
+|adverseReactions=hot flashes, sweating, nausea and vaginal discharge
-|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
-|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
-* Content
-<!--Adult Indications and Dosage-->
-<!--FDA-Labeled Indications and Dosage (Adult)-->
+<!--Black Box Warning-->
-|fdaLIADAdult======Condition1=====
+|blackBoxWarningTitle=<span style="color:#FF0000;">WARNING: QT PROLONGATION : </span>
+|blackBoxWarningBody=<i><span style="color:#FF0000;">WARNING: QT PROLONGATION : </span></i>
-* Dosing Information
+* FARESTON has been shown to prolong the QTc interval in a dose- and concentration-related manner. Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided
-:* Dosage
+<!--Adult Indications and Dosage-->
-=====Condition2=====
+<!--FDA-Labeled Indications and Dosage (Adult)-->
+|fdaLIADAdult=====Indications====
-* Dosing Information
+* FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.
-:* Dosage
-=====Condition3=====
-* Dosing Information
-:* Dosage
-=====Condition4=====
-* Dosing Information
-:* Dosage
-<!--Off-Label Use and Dosage (Adult)-->
-<!--Guideline-Supported Use (Adult)-->
-|offLabelAdultGuideSupport======Condition1=====
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
+====Dosage====
+* The dosage of FARESTON is 60 mg, once daily, orally. Treatment is generally continued until disease progression is observed.
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
+====DOSAGE FORMS AND STRENGTHS====
+* Tablet is 60 mg, round, convex, unscored, uncoated, and white, or almost white, identified with TO 60 embossed on one side.
+|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Non–Guideline-Supported Use (Adult)-->
-|offLabelAdultNoGuideSupport======Condition1=====
+|offLabelAdultNoGuideSupport=* Fracture of vertebral column; Prophylaxis - Prostate cancer, Receiving androgen deprivation therapy<ref name="pmid20723926">{{cite journal| author=Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D et al.| title=Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. | journal=J Urol | year= 2010 | volume= 184 | issue= 4 | pages= 1316-21 | pmid=20723926 | doi=10.1016/j.juro.2010.06.022 | pmc=PMC3047407 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20723926  }} </ref>
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Pediatric Indications and Dosage-->
 <!--FDA-Labeled Indications and Dosage (Pediatric)-->
-|fdaLIADPed======Condition1=====
+|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Off-Label Use and Dosage (Pediatric)-->
 <!--Guideline-Supported Use (Pediatric)-->
-|offLabelPedGuideSupport======Condition1=====
+|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Non–Guideline-Supported Use (Pediatric)-->
-|offLabelPedNoGuideSupport======Condition1=====
+|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Contraindications-->